Edvince receives regulatory approval for phase I/II in subarachnoid haemorrhage (SAH) patients

Edvince received approval from the Danish Medicines Agency for the study ” Interventional, randomised, double-blind, placebo-controlled, multiple-ascending-dose, first-in-human trial to determine the safety and tolerability of the MEK1/2 inhibitor EDV2209 in patients with Subarachnoid Haemorrhage – SAH”, protocol no./code EDV2209_01, EudraCT no. 2021-003629-31

The company is expecting response from the Danish Ethical committee in September/October 2021.